Latikafusp
Based on 1 Customer Validation
Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.Latikafusp may lead to the development of immunogenicity-mediated responses.
For research use only. We do not sell to patients.
- Purity : 97.62%
- CAS No.: 2552814-07-8
- Molecular Weight:159.536 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 lambda1
Recommend Isotype Controls
In Vivo
Latikafusp (10, 30 mg/kg; Weekly doses over three weeks; i.v.) activates both classical and alternative complement pathways[3].
Latikafusp (10, 30 mg/kg; Weekly doses over three weeks; i.v.) causes cynomolgus monkeys in all dose groups to show strong antibody responses, suggesting that the drug has high immunogenicity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkeys [3]
-
Dosage:5 mg/kg; administered on days 1 and 15
-
Administration:i.v.
-
Result:Elicited a strong immunogenic response in all animals, as evidenced by the presence of anti-Latikafusp IgG antibodies on days 15 and 25 following the initial dose administration.
Compared to the 22D4 group alone, the antibody response was significantly higher.
-
Animal Model:Cynomolgus monkeys [3]
-
Dosage:10, 30 mg/kg; Weekly doses over three weeks
-
Administration:i.v.
-
Result:Induced the development of anti-Latikafusp IgG antibodies in all animals by day 19, demonstrating a strong immune response to the therapeutic protein.
Administration in high doses led to severe adverse reactions and immunogenic complications, underscoring critical safety concerns associated with its use.
-
Animal Model:Cynomolgus monkeys [3]
-
Dosage:0, 6, 30, or 150 mg/kg; Weekly doses over four weeks
-
Administration:i.v.
-
Result:At the highest dose of 150 mg/kg, caused severe clinical signs in animals, including weakness, petechiae, hypothermia, and dehydration, which led to the unscheduled euthanasia of several animals.
Additionally, at high doses was linked to immunogenicity-related complications, such as thrombocytopenia and consumptive coagulopathy.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded PD-1 Protein, Human (HEK293, His-Fc, HY-P73345) on HIS1K biosensor, can bind Latikafusp with an affinity constant of 9.162E-11 M as determined in BLI assay.
Chemical Information
-
CAS No. 2552814-07-8
-
Appearance Liquid
-
Molecular Weight 159.536 kDa
-
Color Colorless to light yellow
-
SMILES
[Latikafusp]
-
Synonyms
AMG 256
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Greg Durm, et al. Abstract CT205: Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. [Content Brief]
[3]. Kroenke Met al. Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein. Front Immunol. 2024 Jan 26;15:1345473. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Latikafusp Related Classifications
HY-P99687 Related Classifications
Powered by Bioz